8.5008
price up icon8.76%   0.6808
 
loading
Immunitybio Inc stock is traded at $8.5008, with a volume of 26.51M. It is up +8.76% in the last 24 hours and up +43.06% over the past month. ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.
See More
Previous Close:
$7.82
Open:
$8.21
24h Volume:
26.51M
Relative Volume:
0.78
Market Cap:
$8.75B
Revenue:
$113.29M
Net Income/Loss:
$-351.47M
P/E Ratio:
-21.81
EPS:
-0.3898
Net Cash Flow:
$-309.19M
1W Performance:
-1.90%
1M Performance:
+43.06%
6M Performance:
+227.12%
1Y Performance:
+193.28%
1-Day Range:
Value
$8.20
$8.91
1-Week Range:
Value
$7.77
$8.91
52-Week Range:
Value
$1.83
$12.43

Immunitybio Inc Stock (IBRX) Company Profile

Name
Name
Immunitybio Inc
Name
Phone
(844) 696-5235
Name
Address
3530 JOHN HOPKINS COURT, SAN DIEGO
Name
Employee
691
Name
Twitter
Name
Next Earnings Date
2024-11-06
Name
Latest SEC Filings
Name
IBRX's Discussions on Twitter

Compare IBRX vs VRTX, REGN, ARGX, ALNY, ONC

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
IBRX
Immunitybio Inc
8.515 8.04B 113.29M -351.47M -309.19M -0.3898
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
472.92 121.46B 12.07B 3.95B 3.19B 15.33
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
745.85 78.93B 14.34B 4.50B 3.77B 41.56
Biotechnology icon
ARGX
Argen X Se Adr
703.05 43.87B 4.16B 1.29B 734.26M 19.59
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
314.10 42.07B 3.71B 313.75M 465.38M 2.2571
Biotechnology icon
ONC
Beone Medicines Ltd Adr
284.08 31.65B 5.36B 287.73M 924.18M 2.5229

Immunitybio Inc Stock (IBRX) Upgrades & Downgrades

Date Action Analyst Rating Change
May-20-25 Upgrade Piper Sandler Neutral → Overweight
Mar-06-25 Initiated H.C. Wainwright Buy
Jan-10-25 Initiated BTIG Research Buy
May-12-23 Downgrade Piper Sandler Overweight → Neutral
Aug-03-22 Initiated Jefferies Buy

Immunitybio Inc Stock (IBRX) Latest News

pulisher
01:03 AM

ImmunityBio updates on cell therapy programs (IBRX:NASDAQ) - Seeking Alpha

01:03 AM
pulisher
11:16 AM

ImmunityBio Shares Surge 295% Year-to-Date: Should You Buy, Hold, or Sell? - Bitget

11:16 AM
pulisher
10:49 AM

ImmunityBio Achieves Milestone with Large-Scale NK Cell Production and Cryopreservation from Over 60 Healthy and Cancer Donors - Investing News Network

10:49 AM
pulisher
10:44 AM

Why Is ImmunityBio Stock Soaring On Friday? - Benzinga

10:44 AM
pulisher
10:03 AM

ImmunityBio Stock Soars 295% YTD: Time to Buy, Hold or Sell? - TradingView

10:03 AM
pulisher
08:04 AM

ImmunityBio completes NK cell manufacturing programs - Investing.com

08:04 AM
pulisher
Mar 12, 2026

Why ImmunityBio Stock Is Soaring Today - AOL.com

Mar 12, 2026
pulisher
Mar 12, 2026

ImmunityBio’s (IBRX) Bladder Cancer sBLA Resubmission Tests The Depth Of Its Immuno‑Oncology Strategy - simplywall.st

Mar 12, 2026
pulisher
Mar 12, 2026

Why 2 Small Biotechs May Hold the Key to New Cancer Treatments - MarketBeat

Mar 12, 2026
pulisher
Mar 12, 2026

IBRX Stock Down 10% This Week, But Its CEO Just Outlined 3 Reasons Bull Case Is Intact - Stocktwits

Mar 12, 2026
pulisher
Mar 11, 2026

Assessing ImmunityBio (IBRX) Valuation After FDA Acknowledges Resubmitted ANKTIVA Bladder Cancer Filing - simplywall.st

Mar 11, 2026
pulisher
Mar 11, 2026

ImmunityBio (NASDAQ:IBRX) Stock Price Up 3.2%What's Next? - MarketBeat

Mar 11, 2026
pulisher
Mar 11, 2026

Immunitybio stock initiated at Buy by BTIG with $13 target - Investing.com

Mar 11, 2026
pulisher
Mar 11, 2026

Lucid Tops The Most-Shorted Stock List—Here Are 9 More Short Targets - Benzinga

Mar 11, 2026
pulisher
Mar 11, 2026

IBRX Stock Rout Deepens: Founder Points To Cancer-Fighting Cell Bank Data As Investors Look For Catalyst - Stocktwits

Mar 11, 2026
pulisher
Mar 11, 2026

IBRX Stock Falls -23% In 6-Day Spree On Profit-Taking After 500% YTD Gain - Trefis

Mar 11, 2026
pulisher
Mar 10, 2026

ImmunityBio Earnings Call: ANKTIVA Surge Amid High Burn - TipRanks

Mar 10, 2026
pulisher
Mar 10, 2026

symbol__ Stock Quote Price and Forecast - CNN

Mar 10, 2026
pulisher
Mar 10, 2026

ImmunityBio Faces Potential Setback Amid Director’s Share Sale and Investigation - timothysykes.com

Mar 10, 2026
pulisher
Mar 10, 2026

ImmunityBio’s Immunotherapy ANKTIVA Sparks Revenue Surge as Global Expansion Accelerates (IBRX, NNVC) - marketscreener.com

Mar 10, 2026
pulisher
Mar 10, 2026

Is It Time To Reassess ImmunityBio (IBRX) After Its Recent Share Price Surge - simplywall.st

Mar 10, 2026
pulisher
Mar 10, 2026

FDA Review And Saudi Approval Keep ANKTIVA Central To ImmunityBio Story - Yahoo Finance

Mar 10, 2026
pulisher
Mar 10, 2026

Piper Sandler Keeps an Overweight Rating on ImmunityBio, Inc. (IBRX) - Finviz

Mar 10, 2026
pulisher
Mar 09, 2026

IBRX stock declines — ImmunityBio resubmits Anktiva application to FDA with additional data - MSN

Mar 09, 2026
pulisher
Mar 09, 2026

ImmunityBio (NASDAQ:IBRX) Shares Down 2.5%Should You Sell? - MarketBeat

Mar 09, 2026
pulisher
Mar 09, 2026

ImmunityBio's (IBRX) Buy Rating Reaffirmed at D. Boral Capital - MarketBeat

Mar 09, 2026
pulisher
Mar 09, 2026

Can IBRX Stock Snap Its 4-Day Slide? Founder Promises ‘Game-Changer’ Anktiva Data As FDA Speeds Drug Reviews - Stocktwits

Mar 09, 2026
pulisher
Mar 09, 2026

Behind the Scenes of ImmunityBio's Latest Options Trends - Benzinga

Mar 09, 2026
pulisher
Mar 09, 2026

IBRX Stock Declines — ImmunityBio Resubmits Anktiva Application To FDA With Additional Data - Stocktwits

Mar 09, 2026
pulisher
Mar 09, 2026

ImmunityBio Announces FDA Resubmission For Expanded Use Of Lead Drug - Bitget

Mar 09, 2026
pulisher
Mar 09, 2026

ImmunityBio Announces Resubmission of Supplemental BLA to the FDA for ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC with Papillary Disease Following Agency Review of Additional Data - The Malaysian Reserve

Mar 09, 2026
pulisher
Mar 09, 2026

IBRX Stock Declines Pre-Market — ImmunityBio Resubmits Anktiva Application To FDA With Additional Data - Asianet Newsable

Mar 09, 2026
pulisher
Mar 09, 2026

ImmunityBio Stock Sinks as FDA Review Drags On - TipRanks

Mar 09, 2026
pulisher
Mar 09, 2026

ImmunityBio resubmits bladder cancer application to FDA - Investing.com

Mar 09, 2026
pulisher
Mar 09, 2026

ImmunityBio resubmits sBLA to FDA for Anktiva plus BCG - TipRanks

Mar 09, 2026
pulisher
Mar 09, 2026

FDA seeks more bladder cancer data; ImmunityBio resubmits ANKTIVA bid - Stock Titan

Mar 09, 2026
pulisher
Mar 09, 2026

ImmunityBio’s Stock Sees a Huge Boost - Los Angeles Business Journal

Mar 09, 2026
pulisher
Mar 07, 2026

ImmunityBio (IBRX) Jumps 14% as on Promising Therapy Candidate Results - MSN

Mar 07, 2026
pulisher
Mar 07, 2026

How dovish Fed policy supports ImmunityBio Inc. (26CA) stock2026 Technicals & Weekly Market Pulse Alerts - Naître et grandir

Mar 07, 2026
pulisher
Mar 07, 2026

ImmunityBio (IBRX) soars to new high on Anktiva future expansion - MSN

Mar 07, 2026
pulisher
Mar 07, 2026

Vanguard Group Inc. Boosts Stock Position in ImmunityBio, Inc. $IBRX - MarketBeat

Mar 07, 2026
pulisher
Mar 07, 2026

How ImmunityBio Inc. stock valuations compare to rivalsJuly 2025 Drop Watch & Fast Entry High Yield Tips - Naître et grandir

Mar 07, 2026
pulisher
Mar 07, 2026

Rafferty Asset Management LLC Grows Stake in ImmunityBio, Inc. $IBRX - MarketBeat

Mar 07, 2026
pulisher
Mar 06, 2026

ImmunityBio (NASDAQ:IBRX) Trading Down 3.2%Time to Sell? - MarketBeat

Mar 06, 2026
pulisher
Mar 06, 2026

H.C. Wainwright Raised Its Price Target on ImmunityBio, Inc. (IBRX) to $15 from $10 and Maintains a Buy Rating - Bitget

Mar 06, 2026
pulisher
Mar 06, 2026

ImmunityBio ANKTIVA Milestones Reshape Growth Outlook And Risk Profile - Sahm

Mar 06, 2026
pulisher
Mar 06, 2026

IBRX Founder’s ‘Congrats’ To GSK Sparks Debate After FDA Fast Drug Approvals — Retail Slams Big Pharma Bias Over Anktiva - Stocktwits

Mar 06, 2026
pulisher
Mar 05, 2026

Iovance Biotherapeutics: The High‑Risk Cancer Stock I Think Could Change a Portfolio by 2036 - AOL.com

Mar 05, 2026
pulisher
Mar 05, 2026

ImmunityBio’s Q4 Revenue Gets A Lift From ANKTIVA Sales – IBRX Stock Gains 11% - Stocktwits

Mar 05, 2026
pulisher
Mar 05, 2026

Forget ImmunityBio: This Big‑Cap Pharma Is the Safer Play on Next‑Gen Cancer Therapies - Yahoo Finance

Mar 05, 2026
pulisher
Mar 05, 2026

ImmunityBio Bladder Cancer Milestone Raises Questions On Global ANKTIVA Rollout - Yahoo Finance

Mar 05, 2026

Immunitybio Inc Stock (IBRX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$45.87
price up icon 0.18%
$28.99
price up icon 1.33%
$54.07
price up icon 1.61%
$90.20
price up icon 0.16%
$139.44
price down icon 0.28%
biotechnology ONC
$288.30
price up icon 0.99%
Cap:     |  Volume (24h):